Thrivent Financial For Lutherans increased its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 7.4% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 4,200 shares of the medical research company’s stock after purchasing an additional 290 shares during the quarter. Thrivent Financial For Lutherans’ holdings in Bio-Rad Laboratories were worth $950,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Canada Pension Plan Investment Board bought a new position in Bio-Rad Laboratories in the 2nd quarter worth approximately $113,000. Pacad Investment Ltd. bought a new stake in shares of Bio-Rad Laboratories during the second quarter valued at approximately $113,000. Turner Investments LLC bought a new stake in shares of Bio-Rad Laboratories during the second quarter valued at approximately $136,000. Capital Analysts LLC bought a new stake in shares of Bio-Rad Laboratories during the second quarter valued at approximately $170,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Bio-Rad Laboratories by 12.4% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 815 shares of the medical research company’s stock valued at $184,000 after purchasing an additional 90 shares during the period. Hedge funds and other institutional investors own 62.84% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Thrivent Financial For Lutherans Has $950,000 Position in Bio-Rad Laboratories, Inc. (BIO)” was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/thrivent-financial-for-lutherans-has-950000-position-in-bio-rad-laboratories-inc-bio/1617059.html.

A number of research firms have recently issued reports on BIO. Zacks Investment Research upgraded Bio-Rad Laboratories from a “sell” rating to a “hold” rating in a research report on Wednesday. Jefferies Group LLC reiterated a “buy” rating and issued a $275.00 price target on shares of Bio-Rad Laboratories in a research report on Friday, July 14th. BidaskClub cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, June 14th. Deutsche Bank AG reiterated a “buy” rating and issued a $255.00 price target on shares of Bio-Rad Laboratories in a research report on Monday, September 18th. Finally, TheStreet cut Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research report on Thursday, August 3rd. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. Bio-Rad Laboratories presently has an average rating of “Buy” and a consensus target price of $240.00.

Bio-Rad Laboratories, Inc. (NYSE:BIO) opened at 226.26 on Friday. Bio-Rad Laboratories, Inc. has a 52 week low of $154.89 and a 52 week high of $242.79. The stock’s 50 day moving average price is $221.47 and its 200 day moving average price is $220.14. The firm has a market cap of $6.71 billion, a price-to-earnings ratio of 447.15 and a beta of 0.91.

In related news, EVP Michael Crowley sold 700 shares of the business’s stock in a transaction on Friday, August 11th. The stock was sold at an average price of $215.91, for a total transaction of $151,137.00. Following the sale, the executive vice president now owns 2,060 shares in the company, valued at approximately $444,774.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 28.29% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.